GSK plc (GSK)
| Market Cap | 75.18B |
| Revenue (ttm) | 40.74B |
| Net Income (ttm) | 4.07B |
| Shares Out | 4.08B |
| EPS (ttm) | 0.98 |
| PE Ratio | 18.45 |
| Forward PE | 8.07 |
| Dividend | $1.58 (4.16%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 13,453,960 |
| Open | 37.15 |
| Previous Close | 37.02 |
| Day's Range | 37.13 - 38.90 |
| 52-Week Range | 31.72 - 44.67 |
| Beta | 0.27 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Jul 30, 2025 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
US FDA extends review of GSK's blood cancer drug
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.
GSK shares fall after blood cancer drug likely headed for U.S. rejection
GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects.
FDA Committee Votes Against GSK Blood Cancer Drug Blenrep
The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of therap...
GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an exis...
FDA advisers vote against combination therapies of GSK's blood cancer drug
The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood cancer drug Blenrep for use in combination with other treatments.
US FDA approves pre-filled version of GSK's shingles vaccine
The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, providing patients a more convenient option to receive the shot, the company...
US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine...
FDA staff raises eye damage concerns for GSK's blood cancer drug
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...
GSK seeks FDA nod for expanded use of RSV vaccine in adults
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age...
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
PHILADELPHIA--(BUSINESS WIRE)--GSK begins shipping influenza vaccine doses for the 2025-26 flu season.
GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025
GSK specialty medicines grew YoY in Q1 2025. In fact, it's now their main profit engine, offsetting the weakness in their vaccine segment. Similarly, the company's oncology, HIV, and respiratory biolo...
US Senator investigates GSK for pulling children's asthma inhaler
Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for chil...
Bharat, GSK to halve price of malaria vaccine by 2028
Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday.
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stim...
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic...
GSK says EU heath regulator reviewing expansion of RSV vaccine
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age.
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 ...
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for...
GSK, Spero to stop urinary tract infection drug trial due to early success
Spero Therapeutics and partner GSK said on Wednesday that an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the t...
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually ...
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult pat...
GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic lung disease commonly known as "smoker's lung", the company said on Thursda...
GSK's Blood-Cancer Treatment Combinations Approved in Japan
The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.